Differential Response of Lung Cancer Cells, with Various Driver Mutations, to Plant Polyphenol Resveratrol and Vitamin D Active Metabolite PRI-2191.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
26 02 2021
Historique:
received: 01 02 2021
revised: 11 02 2021
accepted: 22 02 2021
entrez: 3 3 2021
pubmed: 4 3 2021
medline: 20 4 2021
Statut: epublish

Résumé

Plant polyphenols and vitamins D exhibit chemopreventive and therapeutic anticancer effects. We first evaluated the biological effects of the plant polyphenol resveratrol (RESV) and vitamin D active metabolite PRI-2191 on lung cancer cells having different genetic backgrounds. RESV and PRI-2191 showed divergent responses depending on the genetic profile of cells. Antiproliferative activity of PRI-2191 was noticeable in EGFRmut cells, while RESV showed the highest antiproliferative and caspase-3-inducing activity in KRASmut cells. RESV upregulated p53 expression in wtp53 cells, while downregulated it in mutp53 cells with simultaneous upregulation of p21 expression in both cases. The effect of PRI-2191 on the induction of CYP24A1 expression was enhanced by RESV in two KRASmut cell lines. The effect of RESV combined with PRI-2191 on cytokine production was pronounced and modulated. RESV cooperated with PRI-2191 in regulating the expression of IL-8 in EGFRmut cells, while OPN in KRASmut cells and PD-L1 in both cell subtypes. We hypothesize that the differences in response to RESV and PRI-2191 between EGFRmut and KRASmut cell lines result from the differences in epigenetic modifications since both cell subtypes are associated with the divergent smoking history that can induce epigenetic alterations.

Identifiants

pubmed: 33652978
pii: ijms22052354
doi: 10.3390/ijms22052354
pmc: PMC7956761
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Antioxidants 0
Dihydroxycholecalciferols 0
Vitamins 0
1 alpha,24-dihydroxyvitamin D3 60965-80-2
Resveratrol Q369O8926L

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : National Science Centre (NCN)
ID : 2018/31/D/NZ3/01739

Références

J Immunol. 2014 Oct 15;193(8):3835-41
pubmed: 25281753
Aging (Albany NY). 2020 Jan 4;12(1):8-34
pubmed: 31901900
J Steroid Biochem Mol Biol. 2019 Oct;193:105431
pubmed: 31326626
Curr Cancer Drug Targets. 2017;17(7):669-680
pubmed: 28302032
Biochem Pharmacol. 2002 Nov 1;64(9):1375-86
pubmed: 12392819
Sci Rep. 2015 Nov 06;5:16348
pubmed: 26542098
J Androl. 2007 Mar-Apr;28(2):282-93
pubmed: 17050787
Cancer Res. 2005 Nov 1;65(21):9943-52
pubmed: 16267019
J Neurosci. 2013 May 15;33(20):8621-32
pubmed: 23678107
Cancer Biol Ther. 2011 Feb 1;11(3):317-29
pubmed: 21099366
Lung Cancer. 2008 Nov;62(2):193-201
pubmed: 18450321
Nat Rev Cancer. 2014 May;14(5):342-57
pubmed: 24705652
Clinics (Sao Paulo). 2012;67(5):419-24
pubmed: 22666783
J Huazhong Univ Sci Technolog Med Sci. 2007 Oct;27(5):508-12
pubmed: 18060622
Int J Mol Sci. 2015 Nov 13;16(11):27191-207
pubmed: 26580599
Nature. 2003 Sep 11;425(6954):191-6
pubmed: 12939617
Anticancer Res. 2003 Sep-Oct;23(5A):4039-46
pubmed: 14666716
Int J Mol Sci. 2016 Aug 19;17(8):
pubmed: 27548149
Oncogene. 2004 Sep 2;23(40):6702-11
pubmed: 15273734
Oncogene. 2004 Mar 25;23(13):2330-8
pubmed: 14743206
Mol Cell Biol. 2006 Apr;26(7):2782-90
pubmed: 16537920
iScience. 2020 Feb 21;23(2):100820
pubmed: 31981923
J Biol Chem. 2005 Dec 9;280(49):40589-98
pubmed: 16195230
Int J Oncol. 2018 Oct;53(4):1469-1480
pubmed: 30066852
Onco Targets Ther. 2018 Mar 02;11:1157-1171
pubmed: 29535539
J Ovarian Res. 2016 Dec 1;9(1):84
pubmed: 27906095
Leuk Res Treatment. 2012;2012:401784
pubmed: 23259067
PLoS One. 2014 Sep 03;9(9):e106186
pubmed: 25184280
Nature. 2008 Oct 23;455(7216):1069-75
pubmed: 18948947
Infect Agent Cancer. 2019 Oct 18;14:27
pubmed: 31636696
Cancer Res. 2007 Mar 1;67(5):1988-96
pubmed: 17332326
Nutrients. 2016 Sep 09;8(9):
pubmed: 27618095
J Biol Chem. 1994 Apr 8;269(14):10545-50
pubmed: 8144641
Cancer Lett. 2015 Jul 1;362(2):199-207
pubmed: 25846868
J Biol Chem. 2002 Oct 11;277(41):38965-71
pubmed: 12181310
Clin Epigenetics. 2016 May 25;8:61
pubmed: 27226812
J Mol Endocrinol. 2005 Aug;35(1):117-33
pubmed: 16087726
PLoS One. 2013;8(3):e59632
pubmed: 23527233
Front Immunol. 2013 Jun 18;4:148
pubmed: 23785369
Oncotarget. 2013 Jul;4(7):984-94
pubmed: 23846322
Cold Spring Harb Perspect Biol. 2010 Feb;2(2):a001107
pubmed: 20182618
Front Physiol. 2014 Apr 03;5:122
pubmed: 24772087
Reprod Sci. 2012 Sep;19(9):949-61
pubmed: 22534330
PLoS One. 2012;7(10):e48575
pubmed: 23119061
Calcif Tissue Int. 2013 Feb;92(2):77-98
pubmed: 22782502
J Periodontal Res. 2011 Dec;46(6):712-21
pubmed: 21745208
Int J Cancer. 2012 May 15;130(10):2464-73
pubmed: 21732345
Nutr Cancer. 2010;62(6):811-24
pubmed: 20661831
J Biol Chem. 2017 Dec 15;292(50):20657-20668
pubmed: 29061851
Nat Med. 2002 Aug;8(8):793-800
pubmed: 12091876
Endocrinol Metab Clin North Am. 2017 Dec;46(4):1009-1038
pubmed: 29080633
J Steroid Biochem Mol Biol. 2017 Sep;172:117-129
pubmed: 28636886
Int J Cancer. 2006 Jun 15;118(12):3012-21
pubmed: 16395705
Proc Natl Acad Sci U S A. 1990 Dec;87(24):9995-9
pubmed: 2175918
J Cancer. 2017 Jul 15;8(12):2173-2183
pubmed: 28819419
Int J Oncol. 2018 Feb;52(2):337-366
pubmed: 29345296
Int J Mol Sci. 2016 Jul 05;17(7):
pubmed: 27399677
Oncogene. 2002 Oct 7;21(45):6898-907
pubmed: 12362272
Sci Rep. 2018 Feb 2;8(1):2232
pubmed: 29396566
Oncotarget. 2018 Jun 26;9(49):29112-29122
pubmed: 30018739
Int J Mol Med. 2004 Jun;13(6):895-902
pubmed: 15138632
Acta Odontol Scand. 2010 Jul;68(4):239-47
pubmed: 20507262
Aging Dis. 2020 Mar 9;11(2):241-253
pubmed: 32257539
Semin Cancer Biol. 2015 Dec;35 Suppl:S224-S243
pubmed: 25600295
Med Res Rev. 2006 Nov;26(6):747-66
pubmed: 16710860
Mol Cell Endocrinol. 2011 May 16;338(1-2):58-67
pubmed: 21458521
Tumour Biol. 2016 Jun;37(6):7573-82
pubmed: 26687643
Trends Cell Biol. 2006 Feb;16(2):79-87
pubmed: 16406521
Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3895-900
pubmed: 23431171
Am J Physiol Lung Cell Mol Physiol. 2004 Oct;287(4):L774-83
pubmed: 15180920
Int J Mol Sci. 2015 Oct 20;16(10):24873-94
pubmed: 26492238
Oncotarget. 2017 Apr 11;8(15):24177-24186
pubmed: 28412753
Cancers (Basel). 2019 Nov 06;11(11):
pubmed: 31698751
J Nutr Sci Vitaminol (Tokyo). 2010;56(5):326-30
pubmed: 21228504
J Cell Biochem. 2015 Jun;116(6):1130-43
pubmed: 25536521
BMC Cancer. 2013 Jun 18;13:294
pubmed: 23777514
EMBO J. 2002 May 15;21(10):2383-96
pubmed: 12006491
J Steroid Biochem Mol Biol. 2019 Jun;190:139-151
pubmed: 30923017

Auteurs

Ewa Maj (E)

Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 12 Weigla, 53-114 Wrocław, Poland.

Beata Maj (B)

Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 12 Weigla, 53-114 Wrocław, Poland.

Klaudia Bobak (K)

Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 12 Weigla, 53-114 Wrocław, Poland.

Michalina Gos (M)

Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 12 Weigla, 53-114 Wrocław, Poland.

Michał Chodyński (M)

Łukasiewicz Research Network-Industrial Chemistry Institute, 8 Rydygiera, 01-793 Warsaw, Poland.

Andrzej Kutner (A)

Faculty of Mathematics and Natural Sciences, School of Sciences, Institute of Chemical Sciences, Cardinal Stefan Wyszyński University in Warsaw, 1/3 Wóycickiego, 01-938 Warsaw, Poland.

Joanna Wietrzyk (J)

Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 12 Weigla, 53-114 Wrocław, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH